Drug Trial Radar · NCT06867094
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
170
Actual
Start
Mar 28, 2025
Primary completion
Aug 6, 2026
Study completion Oct 12, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study). * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Conditions
- Colitis Ulcerative
Interventions
SAR441566Drug
Pharmaceutical form: Tablet Route of administration: Oral
SAR441566 matching PlaceboDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)Time frame: Week 12
Locations
117 sites in 24 countries. Site status is shown where the registry gives one.
GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003
Sun City, Arizona
Bristol Hospital- Site Number : 8400017
Bristol, Connecticut
Novum Research- Site Number : 8400018
Clermont, Florida
Clinical Research of Osceola- Site Number : 8400012
Kissimmee, Florida
Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002
Miami Lakes, Florida
GCP Clinical Research- Site Number : 8400016
Tampa, Florida
GI Alliance - Glenview- Site Number : 8400005
Glenview, Illinois
Illinois Gastroenterology Group- Site Number : 8400004
Gurnee, Illinois
University of Michigan Health System - Ann Arbor- Site Number : 8400010
Ann Arbor, Michigan
Icahn School of Medicine at Mount Sinai- Site Number : 8400001
New York, New York
Queens Village Primary Medical Center- Site Number : 8400011
Queens Village, New York
NexGen Research- Site Number : 8400020
Lima, Ohio
Frontier Clinical Research - Uniontown- Site Number : 8400006
Uniontown, Pennsylvania
Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400008
Charleston, South Carolina
Gastro Health & Nutrition- Site Number : 8400007
Katy, Texas
SI Research Associates- Site Number : 8400019
Lubbock, Texas
Texas Digestive Disease Consultants - Southlake- Site Number : 8400015
Southlake, Texas
University of Washington Medical Center- Site Number : 8400014
Seattle, Washington
Washington Gastroenterology - Tacoma- Site Number : 8400009
Tacoma, Washington
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320004
San Miguel de Tucumán, Tucumán Province, Argentina
Investigational Site Number : 0360003
Kurralta Park, South Australia, Australia
Investigational Site Number : 0360005
Richmond, Victoria, Australia
Investigational Site Number : 0400002
Salzburg, Austria
Investigational Site Number : 0400001
Vienna, Austria
Investigational Site Number : 0560002
Ghent, Belgium
Investigational Site Number : 0560001
Leuven, Belgium
Hospital de Clinicas de Porto Alegre- Site Number : 0760002
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Ernesto Dornelles- Site Number : 0760003
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site Number : 1000001
Burgas, Bulgaria
Investigational Site Number : 1000003
Rousse, Bulgaria
Investigational Site Number : 1000002
Sofia, Bulgaria
Investigational Site Number : 1240004
Kentville, Nova Scotia, Canada
Investigational Site Number : 1240006
Ajax, Ontario, Canada
Investigational Site Number : 1240005
Richmond Hill, Ontario, Canada
Investigational Site Number : 1240001
Québec, Quebec, Canada
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.